AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 526162: Dibutyl 4-methyl-phenyl phosphate

Chemical compound data from PubChem database. IUPAC Name: dibutyl (4-methylphenyl) phosphate. Molecular Formula: C15H25O4P. Molecular Weight: 300.33. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
The MRC trial of assessment and management of older people in the community: objectives, design and interventions [ISRCTN23494848]

Background
          The benefit of regular multidimensional assessment of older people remains controversial. The majority of trials have been too small to produce adequate evidence to inform policy. Despite the lack of a firm evidence base, UK primary care practitioners (general practitioners) are required to offer an annual health check to patients aged 75 years and over.
        
        
          Design
          Cluster-randomised factorial trial in primary care comparing a package of assessments (i) universal versus targeted assessment and (ii) management by the primary care team (PC) or a multidisciplinary geriatric assessment team (GM). The unit of randomization is the general practice.
        
        
          Methods
          Older people aged 75 and over eligible for the over 75s health check and excluding those in nursing homes or terminally ill were invited to participate. All participants receive a brief assessment covering all areas of the over 75s check. In the universal arm all participants also receive a detailed health and social assessment by a study nurse while in the targeted arm only participants with a pre-determined number and range of problems at the brief assessment go on to have the detailed assessment. The study nurse follows a standard protocol based on results and responses in the detailed assessment to make referrals to (i) the randomised management team (PC or GM) (ii) other medical services, health care workers or agencies (iii) emergency referrals to the GP. The main outcomes are mortality, hospital and institutional admissions and quality of life. 106 practices and 33,000 older people have been recruited to the trial.
Patent AT-E400915-T1: [Translated] WET-RUNNING ELECTRIC DRIVE MOTOR FOR PARTICULARLY A HEATING CIRCULATION PUMP

A motor's can (1) is fitted with a permanent magnet rotor (9) and a displacing device (13) to fill up part of a portion of space in the motor's can, around which the permanent magnet rotor is smaller than a short-circuit rotor. The displacing device fits before/behind the permanent magnet rotor. A first packed device fits in front the permanent magnet rotor. A ring device fits behind the permanent magnet rotor. The displacing device fits rigidly on a drive shaft (8).
Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis

Background
          Sulfasalazine is a widely used anti-inflammatory agent in the treatment of inflammatory bowel disease and several rheumatological disorders. Although as many as 20% of treated patients may experience reversible, dose-dependent side effects, less frequent but potentially severe, systemic reactions have also been reported.
        
        
          Case Presentation
          A severe systemic reaction to sulfasalazine developed in a 21-year old female with rheumatoid arthritis characterized by eosinophilia, granulomatous enteritis and myelotoxicity, cholestatic hepatitis, and seizures. The clinical course and management of this patient are presented as well as a review of the incidence and outcome of severe systemic reactions to sulfasalazine.
        
        
          Conclusions
          Granulomatous myelotoxicity and enteritis developed in a 21 year old female within 3 weeks of initiating sulfasalazine for rheumatoid arthritis. Following a short course of corticosteroids, the patient had resolution of her cholestatic hepatitis, rash, eosinophilia, and gastrointestinal symptoms with no residual manifestations at 7 months follow-up. Although severe reactions to sulfasalazine are rare and unpredictable, practicing physicians should be aware of unusual clinical presentations of toxicity when prescribing sulfasalazine.
Patent AT-E401448-T1: [Translated] STEAM SUPPLY CONTROL DEVICE IN AN IRON

Command device (10) for the delivery of steam in an iron (12). The command device (10) comprises an electric switch (15) arranged in the handle (13), connected to a delivery circuit of the steam (12) in the iron (11), and actuation elements (17, 18) arranged in correspondence with the front part of the handle (13) and connected to the electric switch (15) in order to activate the delivery of the steam (12). The actuation elements (17, 18) are shaped so as to at least partly surround the front part of the handle (13) and can be actuated both frontally and laterally, and also from above with respect to the handle (13) in order to cause the actuation of the electric switch (15).
Seattle: Drug-Related Emergency Department Visits, 2004-2011 - Nonmedical Use of Pharmaceuticals

Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving the nonmedical use of pharmaceuticals (prescription and over-the-counter medications and dietary supplements) for the Seattle metropolitan area, covering 2004-2011.  Nonmedical use includes patients who took a higher than prescribed or recommended dose of their own medication, patients who took a pharmaceutical prescribed for another person, malicious poisoning of the patient by another individual, and documented substance abuse involving pharmaceuticals
Compound 528195: Benzene-1,4-dicarboxylic acid, 2,5-dihydroxy, bis-DTBS

Chemical compound data from PubChem database. IUPAC Name: 2,2,7,7-tetratert-butyl-[1,3,2]dioxasilino[4,5-g][1,3,2]benzodioxasiline-4,9-dione. Molecular Formula: C24H38O6Si2. Molecular Weight: 478.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529970: Ethane, 2-bromo-1-ethoxy-1-(2-methylpropyloxy)

Chemical compound data from PubChem database. IUPAC Name: 2-(2-bromo-1-ethoxyethoxy)propane. Molecular Formula: C7H15BrO2. Molecular Weight: 211.1. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530449: 4-Butylbenzoic acid, undecyl ester

Chemical compound data from PubChem database. IUPAC Name: undecyl 4-butylbenzoate. Molecular Formula: C22H36O2. Molecular Weight: 332.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400917-T1: [Translated] METHOD FOR PRODUCING A MICROMOTOR

PCT No. PCT/EP98/01867 Sec. 371 Date Dec. 1, 1998 Sec. 102(e) Date Dec. 1, 1998 PCT Filed Mar. 31, 1998 PCT Pub. No. WO98/44619 PCT Pub. Date Oct. 8, 1998A micro motor is manufactured by slipping the parts (24a, 24b) of a stator (24) on the mandrel (60) which is placed into an injection mold (50). The motor housing is made by injecting polymer material (63), the stator parts (24a, 24b) being encapsulated in the housing. During injection, a bearing (27) is contained in the injection mold (50). Subsequently, the mandrel (60) is drawn from the stator and a prepared rotor is inserted. Thus, a cost effective and high-precision manufacture of an electric motor with very small dimensions is made possible.
Provider Network Data: 2024 Quarter 4

This Provider Network Data contains information on individual and institutional providers participating in health plan networks from October through December 2024. Plan network data is collected from Medicaid, Commercial, and Exchange plans on a quarterly basis by the Department of Health, including managed care plans, as well as PPO/EPO plans.

For more information, please visit: <a href=https://pndslookup.health.ny.gov>https://pndslookup.health.ny.gov</a>
Patent AT-E401327-T1: [Translated] PYRROLOIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, COMPOSITIONS CONTAINING SAME, AND THEIR USE AS NOOTROPICES

Described herein are new bicyclic arylimidazolones having nootropic action (i.e., protecting and stimulating cerebral functions), analgesic action and anti hyperalgesic action; also described is the process for their preparation and pharmaceutical compositions comprising them, useful for the treatment of cognitive deficits, and of various types of pain.
Nystatin and triamcinolone acetonide

Nystatin and Triamcinolone Acetonide is a prescription ointment combining an antifungal (nystatin) and a corticosteroid (triamcinolone acetonide) to treat skin infections caused by fungi, reducing inflammation and itching. Apply topically as directed. Manufactured by Glenmark Pharmaceuticals Inc., USA. This product is discontinued. This information was generated using AI and is provided for informational and research purposes only.
Indicators for 2022

The CY 2022 Medicare Physician Fee Schedule updates various related policies and CPT/HCPCS codes for the new calendar year.  This includes implementing all recent legislation directed by Congress starting January 1, 2022 and the upcoming conversion factor of $34.6062.  The Geographic Practice Cost Index (GPCI) work floor of 1.0 continues to be extended through the end of CY 2023.  Medicare co-insurance for certain colorectal cancer screening tests will begin its phased in waiver. Mental Health services through telehealth will be expanded following the end of the PHE.
State Only Call

This state-only discussion, sponsored by the Child Welfare Technical Working Group (CWTWG) allowed child welfare information system project managers to air issues, questions, and concerns, and to develop a list of queries and comments for federal response at the end of the meeting.

The topics in this open and interactive session included:

Federal staff did not participate in the first half of the call, so state staff could confidentially raise topics and develop a shared list of comments and questions about CCWIS and other topics of their choice. Questions and comments were displayed on a virtual whiteboard to capture the collective voice of the child welfare information system project managers. The federal analysts joined at the end of the call to respond to the inquiries.

These calls are not recorded.

Metadata-only record linking to the original dataset. Open original dataset below.
MD COVID19 Total Vaccinations Age 65 Plus - At least 1 Dose And Fully Vaccinated

Regarding all Vaccination Data
The date of Last Update is 4/21/2023. Additionally on 4/27/2023 several COVID-19 datasets were retired and no longer included in public COVID-19 data dissemination.

See this link for more information
https://imap.maryland.gov/pages/covid-data

<b>Summary</b>
The cumulative number of COVID-19 vaccinations for persons aged 65+ within a single Maryland jurisdiction: Persons fully vaccinated and those who have received at least one dose.

<b>Description</b>
The MD COVID-19—Persons 65+ Fully Vaccinated layer represents the number of people in each Maryland jurisdiction aged 65 and older who have either received at least one dose of COVID-19 vaccine in a two-dose regimen or are fully vaccinated (have either received a single shot regimen or have completed the second dose in a two-dose regimen), reported each day into ImmuNet.

<b>Terms of Use</b>
The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
DEV DQS Fetal, late fetal, and perinatal mortality rates, by detailed race and Hispanic origin of mother United States

Data on fetal, late fetal, and perinatal mortality rates in the United States, by detailed race and Hispanic origin of mother. Data are from Health, United States. Source: National Center for Health Statistics, National Vital Statistics System, Fetal Death Data Set.
Search, visualize, and download these and other estimates from over 120 health topics with the NCHS Data Query System (DQS), available from: https://www.cdc.gov/nchs/dataquery/index.htm.
NNDSS - TABLE 1F. Brucellosis to Candida auris, clinical

NNDSS - Table 1F. Brucellosis to Candida auris, clinical - 2019. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. 

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published — CDC does not have data because of changes in how conditions are categorized.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2018 and 2019 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the US, a US territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-US Residents' category. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
† Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). 
§ Reporting jurisdictions were informed CDC could receive data for this condition in August 2019. Please note there will be a delay in reporting of case notifications for this condition to CDC.
Patent AT-E400182-T1: [Translated] READY TO BAKE, REFRIGERATED DOUGH

The invention relates to a ready-for-use bakery dough product which can be preserved in the refrigerator and which is prepared from flour, sugar, egg, starch, emulsifiers, baking powder, water and fat, and provided in a bar or block form. This bakery dough is placed in a baking tin and then baked to form individual baked products. In addition, the block can be formed of different dough layers or strips, or each portion can be provided with a different color, decoration or filling. Different doughs can be swirled together to provide a marbled appearance in the block or in the layers or strips. The dough and resulting bakery product can be filled.
Ecdysteroids and oocyte development in the black fly

Background
          Oocyte development was studied in the autogenous black fly, Simulium vittatum (Diptera, Nematocera), a vector of Onchocerca volvulus, the causative agent of onchocerciasis.
        
        
          Results
          Oocyte growth was nearly linear between adult eclosion and was complete by 72 hours at 21°C. The oocyte became opaque at 14 hours after eclosion indicating the initiation of protein yolk deposition. The accumulation of vitellogenin was measured using SDS-PAGE. The density of the yolk protein bands at about 200 and 65 kDa increased during the first and second days after eclosion. The amount of protein in the 200 kDa band of vitellogenin, determined using densitometry, rapidly increased between 12 and 25 hours after eclosion. Ecdysteroid levels were measured using a competitive ELISA. Ecdysteroid levels increased rapidly and subsequently declined during the first day after eclosion.
        
        
          Conclusion
          These data show a correlation between the appearance of vitellogenin in the oocyte, and the rise in ecdysteroids. A possible relationship to molting of the nematode, Onchocerca volvulus, is discussed.
Case report: Survival after deliberate strychnine self-poisoning, with toxicokinetic data

Introduction
          Strychnine poisoning is uncommon, and in most severe cases, the patient dies before reaching hospital. The management of strychnine poisoning is well documented, although there are few data on the kinetics of elimination of strychnine after overdose.
        
        
          Case report
          A 42-year-old man presented shortly after ingestion of an unknown quantity of strychnine powder. After a respiratory arrest, with intensive supportive management requiring admission to an intensive care unit, he survived. Eight serum samples were taken over the first 5 days and analysed subsequently for strychnine concentrations.
        
        
          Results
          The initial concentration at 1.5 hours after ingestion was 4.73 mg/l, falling to 0.38 mg/l at 74 hours postingestion. Serum concentrations followed a monoexponential elimination curve with a calculated elimination half-life of 12 hours.
        
        
          Discussion and conclusion
          Strychnine poisoning presents with classical features, and with early diagnosis and supportive management, the patient can survive. The initial serum concentration of 4.73 mg/l is the highest reported concentration in a patient who has survived. Previous reports of the elimination half-life have suggested it is between 10 and 16 hours, which conforms to the elimination data in our case.
Compound 529404: Pyridine, 3-(4-methylhexyl)

Chemical compound data from PubChem database. IUPAC Name: 3-(4-methylhexyl)pyridine. Molecular Formula: C12H19N. Molecular Weight: 177.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Upregulation of nitric oxide synthase in mice with severe hypoxia-induced pulmonary hypertension

Background
          The importance of nitric oxide (NO) in hypoxic pulmonary hypertension has been demonstrated using nitric oxide synthase (NOS) knockout mice. In that model NO from endothelial NOS (eNOS) plays a central role in modulating pulmonary vascular tone and attenuating hypoxic pulmonary hypertension. However, the normal regulation of NOS expression in mice following hypoxia is uncertain. Because genetically engineered mice are often utilized in studies of NO, we conducted the present study to determine how hypoxia alters NOS expression in wild-type mice.
        
        
          Method
          Mice were exposed to sea level, ambient conditions (5280 feet) or severe altitude (17,000 feet) for 6 weeks from birth, and hemodynamics and lung NOS expression were assessed.
        
        
          Results
          Hypoxic mice developed severe pulmonary hypertension (right ventricular systolic pressure [RVsP] 60 mmHg) as compared with normoxic mice (27 mmHg). Using quantitative reverse-transcription PCR, it was found that expressions of eNOS and inducible NOS (iNOS) increased 1.5-fold and 3.5-fold, respectively, in the lung. In addition, the level of lung eNOS protein was increased, neuronal NOS (nNOS) protein was unchanged, and iNOS was below the limit of detection. Immunohistochemistry demonstrated no change in lung iNOS or nNOS staining in either central or peripheral areas, but suggested increased eNOS in the periphery following hypoxia.
        
        
          Conclusion
          In mice, hypoxia is associated with increases in lung eNOS, possibly in iNOS, but not in nNOS; this suggests that the pattern of lung NOS expression following hypoxia must be considered in studies using genetically engineered mice.
2017 Mental Health Client-level Data (MH-CLD) Annual Report

This report presents results from the Mental Health Client-Level Data (MH-CLD) and Mental Health Treatment Episode Data Set (MH-TEDS) for individuals receiving mental health services from state mental health systems in 2017, as well as selected trends in data collected from such individuals between 2014 and 2017. The report provides information on mental health diagnoses, mental health treatment settings, and demographic and substance use characteristics of individuals in mental health treatment in facilities that reported to individual state administrative data systems. In the 2017 reporting period, 48 states and other jurisdictions submitted 5,835,429 records for individuals receiving mental health services. Alaska, American Samoa, the Federated States of Micronesia, Georgia, Guam, Kansas, Marshall Islands, New Hampshire, New Jersey, U.S. Virgin Islands, and West Virginia had submitted no data or incomplete data for the 2017 reporting period, as of July 1, 2018.
Patent AT-E401185-T1: [Translated] CONTROL METHOD FOR A HOT RUNNER CLOSURE NOZZLE WITH HEATING AND COOLING AGENTS FOR INJECTION MOLDING MACHINES

A shut-off nozzle for hot runner systems of injection molding machines and a method of controlling the same are disclosed. The shut-off nozzle includes a nozzle body (1) having a resin hole (2), a heater (4), and a thermocouple (3) to sense a temperature of the nozzle body (1); a gate tip (8) having a nozzle gate (7) at which the nozzle body (1) comes into contact with a cavity (10) of a mold; a heating unit (5) provided around the gate tip (8) to heat the gate tip (8) by using electricity; and a cooling unit (6) provided around the gate tip (8) in parallel to the heating unit (5), so that a coolant passes through the cooling unit (6) to cool the gate tip (8). In the control method, the nozzle body (1) is primarily heated to a predetermined high temperature by turning on the heater (4). In addition, the gate tip (8) is heated by turning on the heating unit (5), prior to injecting a molten resin into a cavity (10) of a mold through the nozzle gate (7). The heating unit (5) is, thereafter, turned off after an injection of a predetermined amount of the molten resin into the cavity (10) of the mold is completed, thus allowing the gate tip (8) to start to cool. In addition, the cooling unit (6) is operated to quickly cool the gate tip (8). The mold is opened to remove a molded product from the cavity (10) of the mold. <IMAGE>